Genetic and environmental regulation of inflammatory CVD biomarkers Lp-PLA 2 and IgM anti-PC

Atherosclerosis

Volumn 218, Issue 1, 2011, Pages 117-122

  Rahman, Iffat ^a   Atout, Rajai ^b   Pedersen, Nancy L ^a   de Faire, Ulf ^a,c   Frostegård, Johan ^c   Ninio, Ewa ^b   Bennet, Anna M ^a   Magnusson, Patrik K E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INSERM   (France)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti PC; CVD biomarkers; Heritability; Lp PLA 2; Twins

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B; BIOLOGICAL MARKER; IMMUNOGLOBULIN M; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; FEMALE; GENETIC REGULATION; GENETIC VARIABILITY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TWINS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DISEASES IN TWINS; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; IMMUNOGLOBULIN M; INFLAMMATION; MALE; MIDDLE AGED; MODELS, GENETIC; PHOSPHORYLCHOLINE; SWEDEN;

EID: 80052268542     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.04.038     Document Type: Article

References (28)

1. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002, 8:1211-1217.
2. Packard C.J. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Curr Opin Cardiol 2009, 24:358-363.
3. Stremler K.E., Stafforini D.M., Prescott S.M., Zimmerman G.A., McIntyre T.M. An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J Biol Chem 1989, 264:5331-5334.
4. Ninio E., Tregouet D., Carrier J.L., et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet 2004, 13:1341-1351.
5. Oei H.H., van der Meer I.M., Hofman A., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005, 111:570-575.
6. Persson M., Hedblad B., Nelson J.J., Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007, 27:1411-1416.
7. Sabatine M.S., Morrow D.A., O'Donoghue M., et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007, 27:2463-2469.
8. Tsimikas S., Willeit J., Knoflach M., et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J 2009, 30:107-115.
9. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, 375:1536-1544.
10. Guerra R., Zhao B., Mooser V., et al. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res 1997, 38:2281-2288.
11. Detopoulou P., Nomikos T., Fragopoulou E., et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults. Lipids Health Dis 2009, 8:19.
12. Lenzini L, Antezza K., Caroccia B., et al. A twin study of heritability of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity. Atherosclerosis 2009, 205:181-185.
13. Su J., Georgiades A., Wu R., et al. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 2006, 188:160-166.
14. Fiskesund R, Stegmayr B, Hallmans G, et al. Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. Stroke, 41:607-612.
15. Gronlund H., Hallmans G., Jansson J.H., et al. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur J Cardiovasc Prev Rehabil 2009, 16:382-386.
16. de Faire U., Su J., Hua X., et al. Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J Autoimmun 2009.
17. Su J., Hua X., Concha H., et al. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford) 2008, 47:1144-1150.
18. Binder C.J., Horkko S., Dewan A., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003, 9:736-743.
19. Lichtenstein P., De Faire U., Floderus B., et al. The Swedish twin registry: a unique resource for clinical, epidemiological and genetic studies. J Intern Med 2002, 252:184-205.
20. Tselepis A.D, Dentan C., Karabina S.A., Chapman M.J., Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995, 15:1764-1773.
21. Rahman I., Bennet A.M., Pedersen N.L., et al. Genetic dominance influences blood biomarker levels in a sample of 12,000 Swedish elderly twins. Twin Res Hum Genet 2009, 12:286-294.
22. Clyne B., Olshaker J.S. The C-reactive protein. J Emerg Med 1999, 17:1019-1025.
23. Zalewski A., Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005, 25:923-931.
24. Neale M.C., Boker S.M., Xie G., Maes H.H. Mx: statistical modeling 2006, Department of Psychiatry VCU, Richmond, VA.
25. Vinson A., Mahaney M.C., Cox L.A., et al. A pleiotropic QTL on 2p influences serum Lp-PLA2 activity and LDL cholesterol concentration in a baboon model for the genetics of atherosclerosis risk factors. Atherosclerosis 2008, 196:667-673.
26. Kinoshita K., Honjo T. Unique and unprecedented recombination mechanisms in class switching. Curr Opin Immunol 2000, 12:195-198.
27. May A., Wang T.J. Biomarkers for cardiovascular disease: challenges and future directions. Trends Mol Med 2008, 14:261-267.
28. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.